Welcome to our dedicated page for Biostem Tech news (Ticker: BSEM), a resource for investors and traders seeking the latest updates and insights on Biostem Tech stock.
BioStem Technologies reports developments tied to its regenerative medicine business, which develops, manufactures and commercializes perinatal tissue allograft products used by clinicians across wound care and other specialties. Company updates commonly cover financial results, conference calls, clinical research presentations, and product portfolio activity involving brands such as Neox, Clarix, VENDAJE and American Amnion.
BioStem news also includes governance and compliance appointments, board changes, audited financial statement publication, and integration of completed asset acquisitions that expand its surgical and wound-care product offerings. Its disclosures describe proprietary BioRetain, CryoTek and SteriTek processing technologies, AATB-accredited quality systems, and operations aligned with current Good Tissue Practices and current Good Manufacturing Processes.
BioStem Technologies (OTC: BSEM) will present at the Symposium on Advanced Wound Care Spring 2026 in Charlotte, April 8–12. The company will showcase its newly introduced Neox product line, host an Innovation Theater lunch on April 9 (12:15–1:45pm ET, Room 207C) and present poster LR-020 in Exhibit Hall 1C.
Sessions cover randomized controlled trial results on diabetic foot ulcers, real-world evidence, product handling, and clinical adoption guidance for placental and umbilical cord tissue therapies.
BioStem Technologies (OTC: BSEM) announced management will present at the 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026 at 8:45 am ET.
Live and archived webcasts will be available on the company’s investors page at ir.biostemtechnologies.com for interested parties and investors.
BioStem Technologies (OTC: BSEM) announced it filed audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025 on March 30, 2026. The company said publication of audited statements, plus new finance leadership, advances its goal of a Nasdaq uplisting.
BioStem named a new CFO, auditor and audit committee chair and said these steps strengthen financial reporting processes and support corporate initiatives including a potential Nasdaq listing to increase visibility and liquidity.
BioStem Technologies (OTC: BSEM) reported Q4 2025 net revenue of $10.1 million and full-year 2025 revenue of $47.5 million, with Q4 gross margin of 97% and full-year gross margin of 94%. GAAP net loss was ($11.3 million) in Q4 and ($6.6 million) for 2025.
The company completed the BioTissue surgical and wound asset acquisition on Jan 21, 2026, integrated ~20 direct reps plus 30+ agents, and reported cash equivalents of $29.5 million at Dec 31, 2025 (post-close cash ~$16 million).
BioStem Technologies (OTC: BSEM) appointed Jodi Ungrodt to its Board of Directors and named her Audit Committee Chair, effective March 18, 2026. Ungrodt brings 29 years of life‑sciences accounting leadership and is qualified as a financial expert under SEC, NYSE, and NASDAQ rules.
Her experience includes advising 30+ IPOs, serving more than 70 life‑sciences clients at Ernst & Young, and prior audit committee leadership; she will oversee financial reporting, internal controls and risk management as BioStem pursues public‑market visibility in 2026.
BioStem Technologies (OTC: BSEM) will release its fourth quarter and full year 2025 financial results on March 24, 2026 and host a conference call and webcast at 4:30 PM ET.
Presenters include CEO Jason Matuszewski and CFO Brandon Poe. Registration and webcast access are available via the company's provided links and phone numbers.
BioStem Technologies (OTC: BSEM) announced management will present at the 46th Annual TD Cowen Healthcare Conference on Monday, March 2, 2026 at 3:50 pm ET in Boston, MA.
Interested parties can access live and archived webcasts via the company's investors website at ir.biostemtechnologies.com.
BioStem Technologies (OTC: BSEM) highlighted recent U.S. FDA leadership remarks endorsing expanded use of Bayesian statistical methods in clinical trials and tied that openness to its published randomized controlled trial using Bayesian regression and hurdle modeling.
The company said its DFU study showed superior clinical outcomes for BioRetain® processed allografts, with the BR-AC arm almost twice as likely to achieve lasting wound closure versus standard of care. BioStem plans to apply similar Bayesian analyses to ongoing VLU and DFU studies and cited its BioRetain and CryoTek technologies in preserving tissue integrity.
BioTissue (NASDAQ: BESM) completed the sale of its non-ocular Surgical and Wound Care business to BioStem (OTC: BSEM) on Jan 21, 2026. BioStem acquired exclusive rights to the Neox and Clarix product lines, and BioTissue's Surgical sales team and key support staff will join BioStem's commercial organization. BioTissue will continue manufacturing those products for BioStem while refocusing its commercial strategy on ocular therapies, including Prokera, CAM360 AmnioGraft, AmnioGraft, and AmnioGuard. Management frames the divestiture as a move to concentrate resources on eye care innovation and professional education.
BioStem Technologies (OTC: BSEM) closed an asset purchase of BioTissue Holdings' surgical and wound care business, acquiring the Neox and Clarix product lines plus a nationwide sales force and assigned GPO contracts to expand hospital inpatient and outpatient reach.
Deal consideration is an upfront cash payment of approximately $15 million, plus up to $10 million in regulatory milestone payments for 510(k) clearance and up to $15 million in commercial royalty milestones. The acquired assets generated ~$29 million in sales in 2025 and are expected to contribute positive EBITDA to BioStem in 2026. Post-closing cash and restricted cash is approximately $16 million. Barry Hassett was promoted to Chief Commercial Officer. A conference call is scheduled for Jan 22, 2026 at 8:00am ET.